Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Desert Control H1 2026 slides: 500% pilot surge, $2m revenue target

Desert Control H1 2026 slides: 500% pilot surge, $2m revenue target

Desert Control, a Norwegian soil technology company, reported its half-year 2026 performance on August 19. The company saw a dramatic increase in technical pilots, with a sixfold rise, while aiming for a full-year revenue target of approximately $2 million, representing a projected sevenfold increase from 2025. Their Liquid Natural Clay (LNC) technology, aimed at improving water retention in sandy soils, gained traction in agricultural markets facing water scarcity and rising costs in California and Arizona.

The company reported a 317% increase in the number of projects, reaching 50 in the first half of 2026, and a 500% year-over-year increase in Tier 1 pilots. These pilots, covering 66,000 acres, saw a 66% increase in addressable acres. The company had 34 unique customers in 2026, up 209% from 2025, with each project involving an average of 1.44 customers.

Desert Control's Chief Scientific Officer, Mike Canady, emphasized a research strategy moving from mechanism to targeted action, highlighting successful trials in Salinas Valley, California, where LNC increased romaine lettuce yield by 29.8% and improved water use efficiency. The company maintained its 2026 revenue guidance at approximately $2 million, with 89% of the revenue expected from direct sales in the United States and project deliveries.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at investing.com →

More in Finance & Markets

Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with…

  • Moderna's stock jumps 101% after cancer vaccine trial success
  • Estee Lauder earnings exceed expectations, shares rally
  • La-Z-Boy stock falls after missing Q2 sales forecast

More from Wednesday 19 August →